Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.
披露的内容包括但不限于,用于调节趋化因子受体活性的化合物及其使用方法。
[EN] ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS D'ACYLSUFONAMIDE UTILES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR EP3
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2020008317A1
公开(公告)日:2020-01-09
The present invention is directed to acylsulfonamide derivatives of formula (I), pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of, for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.
Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73
作者:Joel W. Beatty、Erick A. Lindsey、Rhiannon Thomas-Tran、Laurent Debien、Debashis Mandal、Jenna L. Jeffrey、Anh T. Tran、Jeremy Fournier、Steven D. Jacob、Xuelei Yan、Samuel L. Drew、Elaine Ginn、Ada Chen、Amber T. Pham、Sharon Zhao、Lixia Jin、Stephen W. Young、Nigel P. Walker、Manmohan Reddy Leleti、Susanne Moschütz、Norbert Sträter、Jay P. Powers、Kenneth V. Lawson
DOI:10.1021/acs.jmedchem.9b01713
日期:2020.4.23
Traditional efforts to inhibit CD73 have involved antibody therapy or the development of smallmolecules, the most potent of which mimic the acidic and ionizable structure of the enzyme's natural substrate, adenosine 5'-monophosphate (AMP). Here, we report the systematic discovery of a novel class of non-nucleotide CD73 inhibitors that are more potent than all other nonphosphonate inhibitor classes reported